Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis. RESEARCH DESIGN AND METHODS: After continuous infusion of low (300 pmol · kg−1 · day−1) or high (24 nmol · kg−1 · day−1) dose of exendin-4 in C57BL/6 or apolipoprotein E–deficient mice (apoE−/−), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes. RESULTS: Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE−/− mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-α and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-κB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI14-22, a protein kinase A–specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b. CONCLUSIONS: Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“Within the cardiovascular system, GLP-1 receptors are expressed on endothelial cells, monocytes, macrophages, and vascular smooth muscle cells (VSMCs) [9].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Similar to lung and pancreatic -cells (24), mice peritoneal macrophages and vascular smooth muscle cells abundantly expressed GLP-1 receptor protein, and the expression level was higher than in freshly isolated endothelial cells.”
ResultGu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575 · cited 1×
“Both TNF- – and MCP-1–deficient mice have significantly reduced atherosclerotic lesions (29,30).”
BackgroundA major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V., Gutierrez-Ramos, J.-C., Connelly, P. W., & Milstone, D. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11871 · Cited by 1,217 · cited 2×
“The adhesion of circulating monocytes to the intimal endothelial cells is thought to be one of the earliest events in the complex pathological process of atherosclerogenesis (14; 15).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“In vascular endothelial cells, GLP-1 stimulates NO production, which may explain the vasodilatory effects in mesenteric arteries (11) and pulmonary artery rings (12).”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundEbato, C., Uchida, T., Arakawa, M., Komatsu, M., Ueno, T., Komiya, K., Azuma, K., Hirose, T., Tanaka, K., Kominami, E., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.009 · Cited by 774 · cited 2×
“) or rabbit anti–glyceraldehyde-3-phosphate dehydrogenase antibody (Cell Signaling Technology, Beverly, MA) as described previously (16).”
BackgroundMethodSelf-citationNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
Background
Cited by
Items 401–500 of 560
Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8
Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9
“demonstrated that GLP-1RA significantly reduced monocyte adhesion to aortic endothelial cells through CD11b in C57BL/6 mice [42].”
BackgroundFiorentino, T. V., & Sesti, G. (2015) · Endocrine · doi:10.1007/s12020-015-0811-7 · Cited by 8
Tang, Z., Liu, L., Guo, Y., Deng, G., Chen, M., & Wei, J. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9345 · Cited by 9
Effects of incretin therapy and bariatric surgery on inflammation in obese patients
Tardio, V., Kellett, S., Bidal-St-Aubin, M., & Tsoukas, M. A. (2018) · Obesity Medicine · doi:10.1016/j.obmed.2018.12.001 · Cited by 8
The critical role of inflammation in atherosclerotic coronary artery heart disease
Spindler, J. S., & Henning, R. J. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103261 · Cited by 8
Anti-inflammatory effects of GLP1-RA drugs
Quintana, L., Tabaza, N., Kurt, B., & Kahles, F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag218 · Cited by 7
He, X. (2022) · European Journal of Inflammation · doi:10.1177/20587392211070402 · Cited by 7
The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 8
“Emerging evidence suggests that GLP-1 exerts direct or indirect effects on vascular endothelium [65, 70, 81, 95, 96] and GLP-1RAs have been shown to play anti-adhesive and anti-inflammatory roles in vascular endothelium [97].”
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
“GLP-1 RAs have been found to protect ischemic myocardium and preserve cardiac function after ischemic cardiac injury [55] , stabilize plaque lesion [56–57] , improve endothelial dysfunction [58] , inhibit macrophage foam cell formation [59] , and suppress platelet activation and aggregation [57] .”
Kataoka, Y., Kitahara, S., Funabashi, S., Makino, H., Matsubara, M., Matsuo, M., Omura‐Ohata, Y., Koezuka, R., Tochiya, M., Tamanaha, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.03.001 · Cited by 7
“In several experimental studies, GLP-1RAs have been shown to inhibit monocyte adhesion to endothelial cells, modulate macrophage phenotypes, and attenuate endothelial dysfunction [11,37 – 39].”
BackgroundBadi, R. M., Khaleel, E. F., El-Bidawy, M. H., Satti, H. H., & Mostafa, D. G. (2020) · Folia Biologica · doi:10.14712/fb2020066050186 · Cited by 8
Komatsu, T., Abe, S., Nakashima, S., Sasaki, K., Higaki, Y., Saku, K., Miura, S.-I., & Uehara, Y. (2023) · Biomolecules · doi:10.3390/biom13020228 · Cited by 8
Zheng, J.-X., Xiao, Y.-C., Hu, Y., Hao, M., & Kuang, H. (2014) · Andrologia · doi:10.1111/and.12252 · Cited by 9
“For example, Arakawa et al. (2010) reported an anti-inflammatory effect of exendin-4 in an animal model of atherosclerosis.”
BackgroundPolu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
Guo, Y., Chu, L., Cai, X., Wu, H., Yan, J., Li, Z., Jiao, R., Bai, S., Yang, W., Lv, F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110867 · Cited by 6
Anti-inflammatory strategies for patients with atherosclerotic coronary disease
Imbesi, A., Greco, A., & Capodanno, D. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2564137 · Cited by 6
“In fact, GLP-1 RAs mitigate systemic inflammation by reducing hs-CRP, IL-6, and TNF-α while enhancing endothelial function [159,160].”
Mitsuhashi, T., Hibi, K., Konishi, M., Maejima, N., Iwahashi, N., Tsukahara, K., Kosuge, M., Ebina, T., Umemura, S., & Kimura, K. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0718 · Cited by 6
Zhang, J., Wu, J., Zeng, W., Zhao, Y., & Zu, H. (2015) · PubMed · Cited by 6
Nozue, T., Takamura, T., Fukui, K., Sozu, T., Tanaka, Y., Hibi, K., Kishi, S., & Michishita, I. (2018) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2018.04.005 · Cited by 6
[Exendin-4 alleviates diabetic cardiomyopathy in mice by regulating Sirt1/PGC1α].
Cai, Y., Zou, S., Fan, C., Wu, C., Fang, S., Li, P., Xue, Y., & Guan, M. (2018) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2018.05.03 · Cited by 11
Nagai, Y., Mukai, K., Otsuki, M., Kimura, T., Kozawa, J., Nishizawa, H., Maeda, N., Matsuoka, T., Iwahashi, H., Imagawa, A., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1585-18 · Cited by 7
Ulambayar, B., Ghanem, A. S., & Nagy, A. C. (2025) · Geriatrics · doi:10.3390/geriatrics10040108 · Cited by 5
“GLP-1 RAs may reduce sepsis risk by suppressing inflammation, including cytokine production and monocyte adhesion, as shown in animal studies via STAT3 and NLRP3 pathways [44,45].”
Muralikrishnan, A. S., Biasin, V., Zabini, D., & Osto, E. (2025) · Acta Physiologica · doi:10.1111/apha.70091 · Cited by 5
“GLP-1R agonism is also known to directly inhibit monocyte adhesion to ECs, leading to an attenuation of the atherosclerotic plaque [177].”
Hu, Z., Tian, D., Yang, Z., Zhang, J., Zhang, L., Xu, Y., & Lu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1754721 · Cited by 7
Fu, M., Li, Q., Qian, H., Min, X., Yang, H., Liu, Z., Wu, W., Zhong, J., Xu, H. Y., Mei, A., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112844 · Cited by 5
Joshi, N., Qasim, M. Z., Kanumilli, S., Shaukat, F., Kumar, A., Mahek, F., Khalid, S., Zeeshan, M., Shaik, M. Y., Nishat, S. M., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002494 · Cited by 6
“Further supporting cardiovascular health, these anti-in fl ammatory and anti-atherogenic properties slow the development and progression of atherosclerotic lesions [50,51] .”
BackgroundChou, O. H. I., Luo, Z., Chung, C. T., Chan, J. S. K., Li, H., Lakhani, I., Lee, S., Lau, D. H. H., Zhang, Q., Liu, T., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.123.034175 · Cited by 6
“53,54 Patients on GLP1as also demonstrated reduced levels of interleu- kin-1 and C-reactive protein.”
The incretin system in type 2 diabetes mellitus: cardiovascular effects
Sukhareva, O. Y., Шмушкович, И. А., Shestakova, E. A., & Shestakova, M. V. (2013) · Problems of Endocrinology · doi:10.14341/probl201258633-42 · Cited by 6
Ntika, S., Tracy, L. M., Franco‐Cereceda, A., Björck, H. M., & Krizhanovskii, C. (2021) · Biomedicines · doi:10.3390/biomedicines9060697 · Cited by 5
Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases
Miyazaki, R., & Miyagi, K. (2023) · Renal Replacement Therapy · doi:10.1186/s41100-023-00492-1 · Cited by 5
Collaborators, S. O. P. E. O. A. O. D. A. (.-A., Irie, Y., Katakami, N., Mita, T., Takahara, M., Matsuoka, T., Gosho, M., Watada, H., & Shimomura, I. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0367-7 · Cited by 5
Self-citationEVOO’s Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?
Amodeo, S., Mirarchi, L., Seidita, A., Citarrella, R., Licata, A., Soresi, M., Iovanna, J., & Giannitrapani, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710120 · Cited by 5
Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System
Ji, X.-J., Hao, J.-W., Li, G., Dong, N., Wang, X., Zhou, M., Zhang, Q., & Yao, Y.-M. (2019) · Mediators of Inflammation · doi:10.1155/2019/2750528 · Cited by 5
“It is possible that the genes for these cytokines undergo synergistic expression upon coactivation of β2-ARs and NF-κB pathway by catecholamine in the setting of burn injury.”
BackgroundMethodResultInfluential[Cardiovascular Effects of Incretin-Based Therapies and Their Therapeutic Potential].
Tyurenkov, I. N., Bakulin, D. A., Куркин, Д. В., & Волотова, Е. В. (2017) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn732 · Cited by 10
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Novel pharmacotherapies and breakthroughs in psoriatic arthritis treatment
Arraf, A., Kharouf, F., & Gladman, D. D. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601050 · Cited by 4
“Animal studies demonstrate significant reductions in macrophage infiltration and local production of IL-6, IL-1β, and TNF-α, notably in vascular inflammation models [85,86].”
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 4
Kahles, F., Rau, M., Reugels, M., Foldenauer, A. C., Mertens, R. W., Arrivas, M. C., Schröder, J. H., Idel, P., Moellmann, J., van der Vorst, E. P. C., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01454-3 · Cited by 5
Aktaş, G. (2025) · Advances in Clinical Pharmacology and Therapeutics · doi:10.63623/8cv4gh26 · Cited by 5
Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
Chilton, R. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000483 · Cited by 4
“Anti-atherosclerotic effects of GLP-1 may be mediated via reduced monocyte/macrophage accumulation in the arterial wall, by inhibiting the inflammatory response in macrophages [42], whereas effects on survival and infarct remodeling post-MI may reflect activation of cardioprotective signaling pathways in the heart [29…”
BackgroundNeff, K., O’Donohoe, P. K., & le Roux, C. W. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1054808 · Cited by 4
“Similarly, an anti-inflammatory outcome has also been demonstrated in an animal model of atherosclerosis using exendin-4 [127].”
BackgroundTherapeutic effect of liraglutide on expression of CTGF and BMP‐7 in induced diabetic nephropathy
Ramzy, M. M., Abdalla, A. M., Zenhom, N. M., Okasha, A., Abdelkafy, A. E., & Saleh, R. K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29015 · Cited by 5
“Moreover, these drugs exert beneficial effects on cardiovascular complications of DM(20) and on the progression of atherosclerosis.(21) Recently, there is a powerful evidence supporting the indication of GLP‐1 analogue if patients are obese, have cardiovascular disease or renal disease as the clinical trials demonstra…”
BackgroundTrusca, V. G., Fuior, E. V., & Gafencu, A. V. (2015) · Current Molecular Medicine · doi:10.2174/1566524016666151123110310 · Cited by 4
Sitagliptin counteracts seasonal fluctuation of glycemic control
Matsuhashi, T. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i6.118 · Cited by 4
Yin, H., Hao, J.-W., Chen, Q., Li, F., Yin, S., Zhou, M., Zhang, Q., Yao, Y.-M., & Chai, J. (2020) · Surgery · doi:10.1016/j.surg.2020.01.004 · Cited by 4
Watada, H. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14346 · Cited by 4
Self-citationState of the Art Review: Glucagon-Like Peptide-1 in Obesity-Related Asthma
Gomez, D. R., Swartzman, I., Linderholm, A., Cummings, B. P., Zeki, A. A., Sundar, K. M., & Kenyon, N. J. (2025) · Lung · doi:10.1007/s00408-025-00861-z · Cited by 3
“GLP-1RAs also reduce macrophage activation and TNF-α expression in vivo through the PKA activa - tion and NF-κB inhibition in an LPS-induced allergic mouse model [121].”
The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations
Lampsas, S., Chardalia, G.-M., Agapitou, C., Papastamopoulos, K., Theodossiadis, P., Siasos, G., Oikonomou, E., Lambadiari, V., & Chatziralli, I. (2026) · Biomedicines · doi:10.3390/biomedicines14051057 · Cited by 3
“…and suppresses TNF-α -induced transcription of pro-inflammatory genes such as Vascular Cell Adhesion Molecule-1 (VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1), E-selectin, and Monocyte Chemoattractant Protein-1 (MCP-1), ultimately reducing monocyte adhesion and early atherogenesis [34–36].”
The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis
Sakız, D., Çalapkulu, M., Sencar, M. E., Bayram, S. M., Ünsal, İ. Ö., Kızılgül, M., Uçan, B., Özbek, M., & Çakal, E. (2022) · Van Medical Journal · doi:10.5505/vtd.2022.09815 · Cited by 3
“Diabetes Mellitus duration (years) (median (min-max)) 9 (1-30)”
Ugwueze, C. V. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_101_24 · Cited by 3
Mijajlovic, M. D., Bornstein, N. M., & Aleksić, V. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251326769 · Cited by 3
“56 59 Atherosclerosis onset is linked to the chronic exposure of endothelial cells to high blood glucose and hyperlipidemic conditions, which, combined with oxidative stress, activate inflammatory responses leading to monocyte and neutrophil adhesion to the endothelium.”
Gliozzi, M., Coppoletta, A. R., Cardamone, A., Carresi, C., Mollace, R., Musolino, V., & Mollace, V. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107744 · Cited by 3
Vascular failure and recent anti-diabetic drugs
Oyama, J., & Node, K. (2017) · Vascular Failure · doi:10.30548/vascfail.1.1_2 · Cited by 3
Bloch, O., Blatt, A., Appel, M. Y., Yehudah, G. B., Cantrell, D., Goldberg, M., Love, I., Khadija, H. A., & Rapoport, M. J. (2021) · Atherosclerosis Plus · doi:10.1016/j.athplu.2021.10.001 · Cited by 3
The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain
Cho, P. G., Jang, J. H., Ko, S., Shin, D. A., Chung, S., & Chang, M. C. (2023) · Biomedicines · doi:10.3390/biomedicines11112990 · Cited by 3
“Previous studies have demonstrated that GLP-1 analogs have modest anti-inflammatory effects by activating adenylate cyclase to produce cyclic adenosine monophosphate, which activates protein kinase A to activate the CAMP response element-binding protein [18–22].”
BackgroundAnti-Inflammatory Effects of Glucagon-Like Peptide-1 Receptor Agonists via the Neuroimmune Axis
Fang, S., & Wong, C. K. (2024) · DNA and Cell Biology · doi:10.1089/dna.2024.0057 · Cited by 3
“…attenuate chronic inflammation in models of diet-induced steatohepatitis and atherosclerosis, reflected by downregulation of proinflammatory cytokine expression in the liver and aorta (Arakawa et al., 2010; McLean et al., 2021a; Rakipovski et al., 2018; Taher et al., 2014; Valdecantos et al., 2018).”
Effect of physical exercise on metabolism in patients with atrial fibrillation
Wang, Y., Weng, S., Xia, C., Xu, T., Song, X., & Wang, F. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1502620 · Cited by 4
shalaby, A. (2014) · Journal of Pharmaceutical Research International · doi:10.9734/bjpr/2014/9297 · Cited by 4
Dan-Shen-Yin has integrated protective effects in diabetic atherosclerosis rat models
Yan, K. (2011) · Journal of Medicinal Plants Research · doi:10.5897/jmpr11.1033 · Cited by 4
“MCP-1 and ICAM-1 play key roles in the process of monocyte transmigration to the subendothelial space (Huo et al., 2001; Arakawa et al., 2010; Rautou et al., 2011; Missiou et al., 2010).”
BackgroundThe Role of Perivascular Fat in the Diagnosis and Prognosis of Atherosclerosis
Polkinghorne, M., West, H. W., & Antoniades, C. A. (2022) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e1 · Cited by 4
Helal, M. M., Almosilhy, N. A., Abo‐elnour, D. E., Jaffal, R., Allam, E. G., Almosilhy, M. A., Batarseh, S. F., & Meshref, M. M. (2026) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2026.2627901 · Cited by 3
“It also reduces microvascular permeability and inhibits lipopolysaccharide (LPS)-induced release of chemokines and cytokines (246,247).”
Regulatory cycles of orexin and glucagon-Like peptide-1 in postviral syndromes
Ruhrländer, J., Schieffer, E., & Schieffer, B. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag009 · Cited by 2
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Ahmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
“GLP-1 receptor agonists may also decrease vulnerable plaque formation, leading to fewer cardiovascular events [176].”
Molecular and clinical roles of incretin-based drugs in patients with heart failure
Orabi, B., Kaddoura, R., Omar, A. S., Carr, C. S., & Alkhulaifi, A. M. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9702-3 · Cited by 2
Shadboorestan, A., Eftekhari, S., Mottaghi-Dastjerdi, N., Shahparvari, R., Tarighi, P., Jahandar, H., Faghihi, H., & Montazeri, H. (2022) · PubMed Central · doi:10.22038/ijbms.2022.64117.14117 · Cited by 3
“(29) also noted the anti-inflammatory effects of GLP-1 analogs in their study.”
BackgroundExendin-4 Exacerbates Burn-Induced Mortality in Mice by Switching to Th2 Response
Hao, J.-W., Chen, Q., Liu, H., & Zhang, Q. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.07.029 · Cited by 2
Bai, S., Lin, C., Jiao, R., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.008 · Cited by 2
Grigorescu, E.-D., Lăcătușu, C.-M., Floria, M., Cazac, G.-D., Onofriescu, A., Sauciuc, L. A., Ceasovschih, A., Crețu, I., Mihai, B. M., & Șorodoc, L. (2023) · Diagnostics · doi:10.3390/diagnostics13172817 · Cited by 4
“Apart from their established antihyperglycemic effects, GLP-1RAs reduce atherosclerotic plaque by inhibiting systemic inflammation, a process which is determined by decreasing leukocyte adhesion and extravasation, as well as decreasing extracellular matrix proteins, independent of the effects on lipid metabolism [42,4…”
BackgroundKamarullah, W., Pranata, R., Wiramihardja, S., & Tiksnadi, B. B. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00695-9 · Cited by 3
Pleiotropic Effects of GLP-1. Cardiovascular Evidence of Effectiveness
Alarcón, P. P., Cascales, A. B. H., Ruiz, A. L., Gil, M. Á. I., Torres, A. H., & Gil, M. D. H. (2013) · Pharmacology & Pharmacy · doi:10.4236/pp.2013.49091 · Cited by 2
“In addition to these cardiovascular effects have been reported in animal studies and human in vitro different actions of analogues of GLP-1 on macrophages and monocytes by decreasing their accumulation in atherosclerotic plaques and reducing production of inflammatory mediators such as TNF-α or CD11b expression [23].”
BackgroundBiological activity studies of the novel glucagon-like peptide-1 derivative HJ07
Han, J. D. J., Sun, L., Qian, H., & Huang, W. (2014) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(14)60093-5 · Cited by 2
Glucagon-like peptide-1 e sistema cardiovascolare: meccanismi fisiopatologici
Avogaro, A. (2010) · Giornale italiano di cardiologia · doi:10.1714/565.6706 · Cited by 2
“Le DPP-4 [anche note come adenosine deaminase complexing protein 2 o cluster differentiation (CD) 26] degradano rapidamente il GLP-1 (7-36) amide a GLP-1 (9-36) amide il quale risulta avere un’affinità 1000 volte inferiore per il recettore del GLP-1 (GLP-1R) e privo di proprietà insulino-tropiche4.”
BackgroundInfluentialKong, Y., Tong, Y. A., Chen, C., Gao, M., Gao, X., & Yao, W. (2016) · Endocrine · doi:10.1007/s12020-015-0831-3 · Cited by 2
Incretin as a Novel Treatment Strategy for NAFLD/NASH
Takeda, Y., Ikeda, R., & Kondo, T. (2016) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.15-00264-2 · Cited by 3
Abood, A., Awad, H., & Hassan, S. M. (2021) · Ain Shams Medical Journal · doi:10.21608/asmj.2021.167313 · Cited by 3
“It, also, suppressed lipopolysaccharide induced NF-κB activetion in macrophages (17) .”
BackgroundChawla, D., Kar, R., Puri, D., & Madhu, S. V. (2023) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2023.22.3.0094 · Cited by 2
Sedky, A. A. (2022) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2022.234979 · Cited by 1
Balk-Møller, E., Hebsgaard, M., Lilleør, N. B., Møller, C. H., Goetze, J. P., & Kissow, H. (2022) · Frontiers in Transplantation · doi:10.3389/frtra.2022.1082634 · Cited by 1
Hirotsu, T., Taniguchi, K., & Nishimura, R. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1520389 · Cited by 1
Kaneto, H., Kimura, T., Sanada, J., Iwamoto, Y., Shimoda, M., Nakanishi, S., & Kaku, K. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70165 · Cited by 1
“In endothelial cells, GLP-1 signaling is known to improve the vascular relaxation response via eNOS expression and activity, which retards the development of atherosclerosis 42 – 44 .”
Sraboni, A., & Farhana, K. M. (2026) · Journal of Biochemistry Pharmacology and Public Health · doi:10.64907/xkmf.v4.i1.jbpph.1 · Cited by 1
Glucagon-like peptide 1 receptor agonists: anti-inflammatory effects in cardiovascular diseases
Bajić, Z., Šobot, T., Stojiljković, M. P., Djuric, D. M., & Škrbić, R. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0021 · Cited by 1
Zawadzki, M., & Karczewska‐Kupczewska, M. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8388511 · Cited by 1
Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk
Kafol, J., Jug, B., & Fras, Z. (2026) · Cells · doi:10.3390/cells15141293 · Cited by 1
“These changes may reduce monocyte adhesion and transendothelial recruitment, thereby inter-rupting an early step in atherogenesis [63,70,71].”
Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
van Maren, S., van Doorn, E. P. M., Smits, M. M., Tack, C. J., van Rossum, E. F. C., & Messaoudi, S. E. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02073-3 · Cited by 1
Kardiovaskuläre Effekte inkretinbasierter Therapien
Lehrke, M., & Marx, N. (2012) · Herz · doi:10.1007/s00059-012-3599-8 · Cited by 1
Siemianowicz, K., Francuz, T., & Garczorz, W. (2012) · Health · doi:10.4236/health.2012.412a225 · Cited by 2
Roan, J., & Tseng, W. (2016) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000169 · Cited by 1
Possible Protective Mechanisms of Sitagliptin against Isoproternol Induced Myocardial Injury in Rat
El‐Bakly, W. M. (2015) · Ain Shams Journal of Forensic Medicine and Clinical Toxicology · doi:10.21608/ajfm.2015.18653 · Cited by 1
Assessment of New Protected Mechanism of Liraglutide on CKD Progression
Luaibi, H. H., Alabbassi, M. G., Raoof, I. B., & Al-Mashhadani, Z. (2021) · Pharmaceutical and Biosciences Journal · doi:10.20510/pbj/9/i2/1283 · Cited by 1
Fujitani, Y. (2012) · Juntendō Igaku/Juntendo igaku · doi:10.14789/pjmj.58.490 · Cited by 1
Self-citationBloch, O., Perl, K., Shimol, A. B., Rotmensh, A., Kagansky, D., Yovel, D. Z., Yehudah, G. B., Cantrell, D., & Rapoport, M. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3635 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Kurt, B., & Kahles, F. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01109-1 · Cited by 1
“Passend hierzu führte GLP-1 in Mono-zyten/Makrophagen zu direkten antiin-flammatorischen Effekten (verminderte Zytokinproduktion und Zelladhäsion am Endothel, [43]).”
BackgroundDear, A. E. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6465-x · Cited by 1
“Several in vivo studies identify atheroprotection by native GLP-1, GLP-1R agonists and DPP-4 inhibitors [9–12].”
BackgroundKheder, M. H. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122879 · Cited by 1
Liu, X., Chen, Z., Zheng, J., Wang, D., & Ying-liang, S. (2023) · Research Square · doi:10.21203/rs.3.rs-2781618/v1 · Cited by 1
Metadata
- Authors
- Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H.
- Affiliations
- Juntendo University (JP)
- Corresponding author
- Mita, Tomoya
- Watada, Hirotaka
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-01-12
- Volume
- 59
- Issue
- 4
- Pages
- 1030-1037
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2844811
- OpenAlex
- W2142097676
- Cited by
- 548
- References
- 38
- Citations by year
- 2026: 31 · 2025: 25 · 2024: 34 · 2023: 27 · 2022: 37 · 2021: 33 · 2020: 27 · 2019: 25 · 2018: 36 · 2017: 32 · 2016: 41 · 2015: 46 · 2014: 36 · 2013: 35 · 2012: 43
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- exendin-4, GLP-1 receptor agonists, monocyte adhesion, endothelial cells, atherosclerosis, macrophage accumulation, ApoE-deficient mice, NF-κB, TNF-α, MCP-1, cAMP signaling, protein kinase A, CD11b, inflammation
- MeSH terms
- Exenatide, Animals, Aorta, Cell Adhesion, Endothelium, Vascular, Flow Cytometry, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Islets of Langerhans, Liver, Lung, Male, Mice, Inbred C57BL, Monocytes, Peptides, Venoms, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.